The Tough Tech problem we are solving
Modern gene editing tools like CRISPR have revolutionized biology, yet significant challenges remain in achieving precision, safety, and scalability for therapeutic and research applications. Current systems often create unintended edits or face biological limitations that restrict their use across cell types and organisms. As a result, scientists and therapeutics developers struggle to perform precise genome modifications efficiently, slowing progress in medicine, synthetic biology, and biotechnology.
About our solution
Neoclease is developing a new generation of programmable endonucleases designed to push the boundaries of what’s possible in gene editing. Through advanced protein engineering and AI-driven design, Neoclease builds ultra-precise gene editing systems that improve targeting accuracy, broaden editing range, and reduce off-target effects. Their platform enables researchers and biopharma partners to unlock more reliable and versatile genome engineering applications—bringing safer, more effective genetic therapies and tools closer to reality.